Esperion Therapeutics, Inc.
US ˙ NasdaqGM ˙ US29664W1053

SecurityESPR / Esperion Therapeutics, Inc.
InstitutionPoint72 Asset Management, L.P.
ManagerSteven Cohen
Latest Disclosed Ownership209,971 shares
Ownership 0.20%
Point72 Asset Management, L.P. ownership in ESPR / Esperion Therapeutics, Inc.

2024-02-14 - Point72 Asset Management, L.P. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 209,971 shares of Esperion Therapeutics, Inc. (US:ESPR). This represents 0.2 percent ownership of the company. In their previous filing dated 2023-04-05 , Point72 Asset Management, L.P. had reported owning 4,533,756 shares, indicating a decrease of -95.37 percent.

Point72 Asset Management, L.P. has a history of taking positions in derivatives of the underlying security (ESPR) in the form of stock options.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2024-02-14 2024-02-14 13G/A 4,533,756 209,971 -95.37 0.20 -96.00
2023-04-05 2023-04-05 13G 2,438,138 4,533,756 85.95 5.00 19.05
2023-02-14 2023-02-14 13G/A 3,470,278 2,438,138 -29.74 4.20 -19.23
2022-08-23 2022-08-23 13G 3,470,278 5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ESPR / Esperion Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 1,689,372 1,689,372 4,629 0.0059
2026-02-17 2025-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -2,201 -100.00 0 -100.00
2025-11-14 2025-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 2,201 2,201 6 0.0000
2024-11-14 2024-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -67,070 -100.00 0 -100.00
2024-09-16 2024-06-30 13F/A-2 ESPERION THERAPEUTICS INC NE COM 29664W105 67,070 51,000 317.36 149 244.19 0.0004
2024-08-19 2024-06-30 13F/A-1 ESPERION THERAPEUTICS INC NE COM 29664W105 67,070 51,000 149 0.0004
2024-08-14 2024-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 67,070 51,000 149 0.0004
2024-05-15 2024-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 16,070 11,270 234.79 43 207.14 0.0001
2024-02-14 2023-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 4,800 -3,093,052 -99.85 14 -99.54 0.0000
2023-11-14 2023-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 3,097,852 -1,877,148 -37.73 3,036 -56.11 0.0089
2023-08-14 2023-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 4,975,000 1,375,000 38.19 6,915 20.81 0.0206
2023-05-15 2023-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 3,600,000 1,323,000 58.10 5,724 -59.65 0.0177
2023-05-15 2022-12-31 13F/A-1 ESPERION THERAPEUTICS INC NE COM 29664W105 2,277,000 -511,300 -18.34 14,186 -24.07 0.0482
2023-02-14 2022-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 2,277,000 -511,300 14,186 0.0482
2022-11-14 2022-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 2,788,300 1,725,204 162.28 18,682 176.32 0.0746
2022-08-15 2022-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 1,063,096 1,063,096 6,761 0.0285
2021-08-16 2021-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -648,200 -100.00 0 -100.00
2021-05-17 2021-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 648,200 648,200 18,182 0.0849
2020-05-15 2020-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -4,800 -100.00 0 -100.00
2020-02-14 2019-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 4,800 -414,590 -98.86 286 -98.14 0.0015
2019-11-15 2019-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 419,390 352,617 528.08 15,375 395.01 0.0944
2019-08-14 2019-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 66,773 -150,327 -69.24 3,106 -64.37 0.0162
2019-05-15 2019-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 217,100 217,100 225.13 8,717 180.65 0.0396
2019-02-14 2018-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -507,300 -100.00 0 -100.00
2018-11-14 2018-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 507,300 143,200 39.33 22,509 57.75 0.0928
2018-08-14 2018-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 364,100 364,100 14,269 0.0569
2016-02-16 2015-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -77,000 -100.00 0 -100.00
2015-11-16 2015-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 77,000 38,200 98.45 1,816 -42.75 0.0143
2015-08-14 2015-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 38,800 38,800 -49.61 3,172 74.67 0.0220
2015-05-15 2015-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -10,700 -100.00 0 -100.00
2015-02-17 2014-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 10,700 10,700 433 0.0030
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-14 2024-09-30 13F ESPERION THERAPEUTICS INC NE COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-09-16 2024-06-30 13F/A ESPERION THERAPEUTICS INC NE COM Put 260,000 30.00 577 7.65 n/a n/a n/a
2024-08-19 2024-06-30 13F/A ESPERION THERAPEUTICS INC NE COM Put 260,000 577 n/a n/a n/a
2024-08-14 2024-06-30 13F ESPERION THERAPEUTICS INC NE COM Put 260,000 577 n/a n/a n/a
2024-05-15 2024-03-31 13F ESPERION THERAPEUTICS INC NE COM Put 200,000 536 n/a n/a n/a
2023-05-15 2023-03-31 13F ESPERION THERAPEUTICS INC NE COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-15 2022-12-31 13F/A ESPERION THERAPEUTICS INC NE COM Put 150,000 200.00 934 178.81 n/a n/a n/a
2023-02-14 2022-12-31 13F ESPERION THERAPEUTICS INC NE COM Put 150,000 934 n/a n/a n/a
2022-11-14 2022-09-30 13F ESPERION THERAPEUTICS INC NE COM Put 50,000 335 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.